Your browser doesn't support javascript.
loading
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.
Correll, Christoph U; Højlund, Mikkel; Graham, Christine; Todtenkopf, Mark S; McDonnell, David; Simmons, Adam.
Afiliación
  • Correll CU; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA.
  • Højlund M; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
  • Graham C; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
  • Todtenkopf MS; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • McDonnell D; Department of Psychiatry Aabenraa, Mental Health Services Region of Southern Denmark, Aabenraa, Denmark.
  • Simmons A; Alkermes, Inc., Waltham, Massachusetts, USA.
Int J Neuropsychopharmacol ; 26(7): 451-464, 2023 07 31.
Article en En | MEDLINE | ID: mdl-37326421
ABSTRACT

BACKGROUND:

Patients with first-episode psychosis or early-phase schizophrenia are susceptible to olanzapine-associated weight gain and cardiometabolic dysregulation. This meta-analysis characterized weight and metabolic effects observed during olanzapine treatment in randomized clinical trials in this vulnerable patient population.

METHODS:

PubMed, EMBASE, and Dialog were searched for randomized controlled trials (RCTs) reporting weight or cardiometabolic outcomes associated with olanzapine treatment in first-episode psychosis or early-phase schizophrenia. Random-effects meta-analysis and meta-regression were conducted using R v4.0.5.

RESULTS:

Of 1203 records identified, 26 RCTs informed the analyses. The meta-analytic mean (95% CI) weight gain was 7.53 (6.42-8.63) kg in studies (n = 19) that reported weight gain with olanzapine treatment. Stratified by duration, the mean (95% CI) weight gain was significantly higher in studies >13 weeks in duration than in those lasting ≤13 weeks 11.35 (10.05-12.65) vs 5.51 (4.73-6.28) kg, respectively. Despite between-study variability, increases from baseline in most glycemic and lipid parameters were generally small in studies of both ≤13 and >13 weeks. There were no correlations, however, between weight gain and metabolic parameter changes when stratified by study duration.

CONCLUSIONS:

In RCTs enrolling patients with first-episode psychosis or early-phase schizophrenia, olanzapine was consistently associated with weight gain that was greater in studies lasting >13 weeks compared with those of ≤13 weeks. Metabolic changes observed across studies suggest that RCTs may underestimate metabolic sequelae vs real-world treatment observations. Patients with first-episode psychosis or early-phase schizophrenia are vulnerable to olanzapine-associated weight gain; strategies minimizing olanzapine-associated weight gain should be carefully considered.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Esquizofrenia / Antipsicóticos / Enfermedades Cardiovasculares Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Int J Neuropsychopharmacol Asunto de la revista: NEUROLOGIA / PSICOFARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Esquizofrenia / Antipsicóticos / Enfermedades Cardiovasculares Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Int J Neuropsychopharmacol Asunto de la revista: NEUROLOGIA / PSICOFARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos